NCLEX Review Guide: Hepatic Medications

Hepatoprotective Agents

• Milk Thistle (Silymarin): Acts as an antioxidant by reducing free radical production and lipid peroxidation, while also inhibiting hepatotoxins from binding to receptor sites on hepatocyte cell membranes. Clinical studies suggest potential benefit in alcoholic liver disease, viral hepatitis, and toxin-induced liver damage.
• N-acetylcysteine (NAC): Serves as a glutathione precursor that replenishes hepatic glutathione stores depleted during acetaminophen toxicity. It's most effective when administered within 8-10 hours of acetaminophen overdose and is the standard antidote for acetaminophen poisoning.

Medications for Portal Hypertension

• Beta-Blockers (Propranolol, Nadolol): Reduce portal pressure by decreasing cardiac output (β1 effect) and causing splanchnic vasoconstriction (β2 blockade), effectively reducing blood flow to the portal system. These medications are used prophylactically to prevent first variceal bleeding in patients with medium to large esophageal varices.
• Vasopressin and Terlipressin: Potent splanchnic vasoconstrictors that reduce portal blood flow and pressure during acute variceal bleeding. Due to significant systemic vasoconstriction effects, they are typically administered with nitroglycerin to minimize cardiac complications.
• Somatostatin and Octreotide: Inhibit the release of vasodilatory peptides, causing selective splanchnic vasoconstriction without significant systemic effects. Octreotide is often used as first-line pharmacological therapy for acute variceal bleeding alongside endoscopic intervention.

Medications for Hepatic Encephalopathy

• Lactulose: A non-absorbable disaccharide that functions as an osmotic laxative and reduces ammonia production and absorption. It works by acidifying colonic contents, trapping ammonia as non-absorbable ammonium, and promoting the growth of non-urease-producing bacteria that reduce ammonia production.
• Rifaximin: A minimally absorbed oral antibiotic that reduces intestinal ammonia production by decreasing the population of ammonia-producing gut bacteria. It's often used in combination with lactulose for prevention of recurrent episodes of hepatic encephalopathy.
• L-Ornithine L-Aspartate (LOLA): Provides substrates for the urea cycle and glutamine synthesis, enhancing ammonia detoxification in skeletal muscle and liver. Clinical studies show it can improve mental status and reduce ammonia levels in patients with hepatic encephalopathy.

Lactulose overdose can lead to severe diarrhea, dehydration, and electrolyte imbalances. Monitor patients closely for signs of dehydration and adjust dosage to achieve target stool frequency.

Diuretics for Ascites Management

• Spironolactone: A potassium-sparing diuretic that competitively blocks aldosterone receptors in the distal tubule, reducing sodium reabsorption and potassium excretion. It's particularly effective in cirrhotic ascites due to the secondary hyperaldosteronism present in these patients.
• Furosemide: A loop diuretic that inhibits the sodium-potassium-chloride cotransporter in the ascending loop of Henle, causing increased sodium, potassium, and water excretion. In ascites management, it's typically used in combination with spironolactone to enhance diuresis and prevent electrolyte imbalances.

Monitor patients on diuretic therapy for hepatorenal syndrome, which can be precipitated by excessive diuresis. Signs include rising creatinine, oliguria, and decreasing sodium levels.

Ascites Management Protocol

1. Restrict sodium intake to 2000mg/day and fluid to 1.5L/day if hyponatremic
2. Start spironolactone 100mg and furosemide 40mg daily
3. Weigh patient daily to assess response
4. Titrate doses maintaining 100:40 ratio up to maximum of 400mg spironolactone and 160mg furosemide
5. Monitor electrolytes, BUN, creatinine twice weekly during dose adjustments
6. Consider paracentesis if inadequate response to maximum diuretic therapy

Medications for Hepatitis B

• Entecavir: A guanosine nucleoside analogue that inhibits HBV DNA polymerase, preventing viral replication. It has a high genetic barrier to resistance, making it a preferred first-line agent for chronic hepatitis B treatment with minimal side effects and rare resistance development.
• Tenofovir: A nucleotide analogue that inhibits HBV reverse transcriptase, effectively suppressing viral replication. Available as tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), with TAF having less renal and bone toxicity while maintaining similar efficacy.
• Pegylated Interferon alfa-2a: A modified interferon with immunomodulatory, antiproliferative, and antiviral properties that enhances the body's immune response against HBV-infected hepatocytes. It offers a finite treatment duration (48 weeks) but has more side effects than nucleos(t)ide analogues.

Medications for Hepatitis C

• Direct-Acting Antivirals (DAAs): Target specific steps in the HCV life cycle to prevent viral replication. Modern regimens typically combine multiple DAAs with different mechanisms to achieve high cure rates (>95%) with 8-12 weeks of therapy and minimal side effects.
• Sofosbuvir/Velpatasvir: A pangenotypic combination that inhibits both NS5B polymerase (sofosbuvir) and NS5A protein (velpatasvir), effective against all HCV genotypes. This once-daily combination can treat most patients regardless of cirrhosis status with a simple 12-week regimen.
• Glecaprevir/Pibrentasvir: Combines an NS3/4A protease inhibitor (glecaprevir) with an NS5A inhibitor (pibrentasvir) to create a pangenotypic regimen that can be used for as little as 8 weeks in treatment-naïve patients without cirrhosis.

Always check for drug interactions before starting DAA therapy, particularly with acid-reducing medications, statins, and anticonvulsants. Some combinations may be contraindicated or require dose adjustments.

Ursodeoxycholic Acid (UDCA)

• Ursodeoxycholic acid is a hydrophilic bile acid that displaces toxic bile acids from the bile acid pool, protects hepatocytes from cytotoxic effects of bile acids, and has immunomodulatory and anti-inflammatory properties. It's the mainstay of treatment for primary biliary cholangitis (PBC) and is also used in other cholestatic conditions.
• The standard dosage for PBC is 13-15 mg/kg/day, which can delay disease progression, improve liver biochemistry, and potentially extend survival when started in early stages. Approximately 60% of patients with PBC will respond to UDCA therapy with improvement in liver biochemistry.

Obeticholic Acid

• Obeticholic acid is a farnesoid X receptor (FXR) agonist that regulates bile acid synthesis and transport, reducing bile acid production and increasing bile flow. It's approved for PBC patients with inadequate response or intolerance to UDCA, either as monotherapy or in combination with UDCA.
• The starting dose is 5 mg daily, which may be increased to 10 mg daily after 3 months if tolerated and necessary. The most common side effect is pruritus, which can be severe enough to require dose reduction or discontinuation in some patients.

Obeticholic acid can cause significant LDL cholesterol elevation. Monitor lipid profiles during therapy and consider lipid-lowering medication if necessary.

Cholestyramine and Other Bile Acid Sequestrants

• Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting their excretion. While not disease-modifying, it's highly effective for managing pruritus associated with cholestatic liver diseases by reducing circulating levels of pruritogenic bile acids.
• Typical dosing is 4-16 g daily divided into 2-4 doses, with timing carefully separated from other medications (at least 4 hours before or after) to prevent interference with absorption. Other bile acid sequestrants include colestipol and colesevelam, which have similar efficacy but may differ in palatability and convenience.

Essential Hepatic Medications

• N-acetylcysteine: The antidote for acetaminophen toxicity, most effective when given within 8-10 hours of overdose. Works by replenishing glutathione stores in the liver.
• Beta-blockers: First-line for prevention of variceal bleeding in portal hypertension. Non-selective agents (propranolol, nadolol) are preferred due to both β1 and β2 blocking effects.
• Lactulose: First-line treatment for hepatic encephalopathy. Acts by trapping ammonia in the gut and reducing ammonia-producing bacteria.
• Rifaximin: Add-on therapy for hepatic encephalopathy that reduces recurrence rates. Minimal systemic absorption limits side effects.
• Spironolactone and Furosemide: Combination diuretic therapy for ascites, typically in a 100mg:40mg ratio to maintain electrolyte balance.
• Entecavir and Tenofovir: First-line antivirals for chronic hepatitis B with high barriers to resistance.
• Direct-Acting Antivirals: Curative therapy for hepatitis C with >95% success rates in 8-12 weeks.
• Ursodeoxycholic Acid: First-line treatment for primary biliary cholangitis that can delay disease progression.

Commonly Confused Points

Study Tips